
Gerard Criner, MD, discusses mucus plugging, multimorbidity, and moderate exacerbation risk in COPD from the GOLD 2026 conference in Philadelphia.





Gerard Criner, MD, discusses mucus plugging, multimorbidity, and moderate exacerbation risk in COPD from the GOLD 2026 conference in Philadelphia.

Gerard Criner, MD, reviews GOLD 2026 sessions on mucus plugs and inhaler technique, plus multimorbidity, exacerbation risk, and the 2027 GOLD Report.

Dave Singh, MD, discusses IL-33 inhibition for non-type 2 COPD, 2027 GOLD report refinements, and how to view biologics not yet in the GOLD algorithm.

Most patients with type 2 COPD also have non-type 2 inflammation, shaping how clinicians may use targeted and anti-alarmin biologics, per Dave Singh, MD.

The 2027 GOLD report recommends a LAMA for group A, defines 6 pre-COPD types, and expands CT, rehabilitation, and cardiovascular guidance for COPD.

IL-33-targeted therapy may reach most patients with COPD regardless of eosinophil count, but questions remain about how drugs act on its 2 forms.

Dave Singh, MD, reflects on 2027 GOLD report refinements, from mucus plugs and early COPD to biologics awaiting regulatory approval.

Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.

IL-33 has 2 forms in COPD: oxidized IL-33 drives mucus dysfunction, while reduced IL-33 recruits inflammatory cells, with implications for mucus plugging.

Alvar Agustí, MD, previews key 2027 GOLD report changes, from initial COPD treatment and new biologic data to a GOLD Science Committee call to action.

Type 2 biologics reduced mucus plugs in asthma trials, and quantitative imaging may help detect this treatable phenotype, according to a GOLD 2026 session.

CT-detected mucus plugs affect up to 67% of patients with COPD and are linked to worse lung function, exacerbations, and mortality, even without symptoms.

At GOLD 2026, Alvar Agustí, MD, PhD, speaks on COPD underdiagnosis and misdiagnosis, barriers to spirometry in primary care, and managing pre-COPD.

HCPLive previews GOLD 2026 in Philadelphia, November 5-6, with sessions on the 2027 GOLD Report, mucus plugging, and exacerbations, plus expert interviews.

AI models have not outperformed existing clinical scores for COPD prognosis, but home monitoring may help track disease activity, Bourbeau said.

Jean Bourbeau, MD, says AI analysis of CT scans is not ready for routine use but could reshape early COPD diagnosis as GOLD expands its AI guidance.

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Vogelmeier, of Philipps-University of Marburg discusses pooled data showing reduced COPD exacerbations, though most effectively in former smokers.

Agusti, chair of the GOLD Board of Directors, discusses which COPD diagnostic bottleneck AI is closest to solving and more.

Hanania explains how IL-33 inhibitors including itepekimab and astegolimab may uniquely benefit COPD exacerbation.

Barr discusses the means to encourage systemic adoption of low dose CT scans to help curb the deadliest cancer in the US.

Halpin reviews the state of triple therapy inhaler prescribing strategies in the era of new biologic options.

Vogelmeier discusses major changes to the annual COPD report, including a broader threshold for escalating treatment after exacerbation.

COPD is not a complex disease, Polverino explains. It's only complex to treat because of limited understanding.

Polverino stresses the need for prospective analysis to validate CC16 and mucus plugs as viable biomarkers for COPD status.

Bakhos explains the ideal patient population and strategies inherent to LVRS success.

Friedberg explains how an emphasis on physical fitness prior to and after surgery can significantly better long-term outcomes.

Friedberg discusses the inconsistent clinical pathways from disease progression to intervention in patients with a pair of highly deadly lung diseases.